Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Collaborative Groups / Breast and Gynecologic Cancers Research Group / FDA approved autoantibody panel identified as potential serum biomarker for triple-negative breast cancer

FDA approved autoantibody panel identified as potential serum biomarker for triple-negative breast cancer

OVA1 for Ovarian Cancer

Click here to visit the biomarker database for more information on OVA1.

News

The final report of the 2013 Cancer Biomarkers Bioinformatics Workshop is now available.

Announcement 06/26/2014


Please click here to register for the 9th EDRN Scientific Workshop from September 8-10, 2014, in Bethesda, Maryland. The meeting registration page also has agendas and hotel reservation information.
Announcement 06/05/2014


Funding Opportunity Available

Both RFAs for Molecular and Cellular Characterization of Screen-Detected Lesions have been published.

RFA-CA-14-010.html

and

RFA-CA-14-011.html